These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
309 related articles for article (PubMed ID: 26086825)
1. Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted? Lima A; Bernardes M; Azevedo R; Medeiros R; Seabra V Int J Mol Sci; 2015 Jun; 16(6):13760-80. PubMed ID: 26086825 [TBL] [Abstract][Full Text] [Related]
2. SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients. Lima A; Bernardes M; Azevedo R; Monteiro J; Sousa H; Medeiros R; Seabra V Toxicol Sci; 2014 Nov; 142(1):196-209. PubMed ID: 25124723 [TBL] [Abstract][Full Text] [Related]
3. Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome. Lima A; Bernardes M; Azevedo R; Seabra V; Medeiros R Pharmacogenomics; 2016 Oct; 17(15):1649-1674. PubMed ID: 27676277 [TBL] [Abstract][Full Text] [Related]
4. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. Ranganathan P; Culverhouse R; Marsh S; Mody A; Scott-Horton TJ; Brasington R; Joseph A; Reddy V; Eisen S; McLeod HL J Rheumatol; 2008 Apr; 35(4):572-9. PubMed ID: 18381794 [TBL] [Abstract][Full Text] [Related]
5. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Kooloos WM; Wessels JA; van der Straaten T; Allaart CF; Huizinga TW; Guchelaar HJ Pharmacogenomics; 2010 Feb; 11(2):163-75. PubMed ID: 20136356 [TBL] [Abstract][Full Text] [Related]
6. Role of key TYMS polymorphisms on methotrexate therapeutic outcome in portuguese rheumatoid arthritis patients. Lima A; Seabra V; Bernardes M; Azevedo R; Sousa H; Medeiros R PLoS One; 2014; 9(10):e108165. PubMed ID: 25279663 [TBL] [Abstract][Full Text] [Related]
7. Association of dihydrofolate reductase (DHFR) -317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis. Milic V; Jekic B; Lukovic L; Bunjevacki V; Milasin J; Novakovic I; Damnjanovic T; Popovic B; Maksimovic N; Damjanov N; Radunovic G; Pejnovic N; Krajinovic M Clin Exp Rheumatol; 2012; 30(2):178-83. PubMed ID: 22324981 [TBL] [Abstract][Full Text] [Related]
8. Expression of methotrexate transporters and metabolizing enzymes in rheumatoid synovial tissue. Stamp LK; Hazlett J; Highton J; Hessian PA J Rheumatol; 2013 Sep; 40(9):1519-22. PubMed ID: 23858048 [TBL] [Abstract][Full Text] [Related]
11. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Wessels JA; van der Kooij SM; le Cessie S; Kievit W; Barerra P; Allaart CF; Huizinga TW; Guchelaar HJ; Arthritis Rheum; 2007 Jun; 56(6):1765-75. PubMed ID: 17530705 [TBL] [Abstract][Full Text] [Related]
12. Folate metabolic pathway single nucleotide polymorphisms: a predictive pharmacogenetic marker of methotrexate response in Indian (Asian) patients with rheumatoid arthritis. Ghodke-Puranik Y; Puranik AS; Shintre P; Joshi K; Patwardhan B; Lamba J; Niewold TB; Chopra A Pharmacogenomics; 2015 Dec; 16(18):2019-34. PubMed ID: 26616421 [TBL] [Abstract][Full Text] [Related]
13. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Wessels JA; Kooloos WM; De Jonge R; De Vries-Bouwstra JK; Allaart CF; Linssen A; Collee G; De Sonnaville P; Lindemans J; Huizinga TW; Guchelaar HJ Arthritis Rheum; 2006 Sep; 54(9):2830-9. PubMed ID: 16947783 [TBL] [Abstract][Full Text] [Related]
14. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis. Drozdzik M; Rudas T; Pawlik A; Gornik W; Kurzawski M; Herczynska M Pharmacogenomics J; 2007 Dec; 7(6):404-7. PubMed ID: 17325736 [TBL] [Abstract][Full Text] [Related]
15. Polymorphism in Organic Anion-Transporting Polypeptide Gene Related to Methotrexate Response in Rheumatoid Arthritis Treatment. Takahashi K; Nakamura H; Watanabe A; Majima T; Koiwa M; Kamada T; Takai S J Nippon Med Sch; 2019; 86(3):149-158. PubMed ID: 31292326 [TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics and pharmacogenomics for rheumatoid arthritis responsiveness to methotrexate treatment: the 2013 update. Zhu H; Deng FY; Mo XB; Qiu YH; Lei SF Pharmacogenomics; 2014 Mar; 15(4):551-66. PubMed ID: 24624921 [TBL] [Abstract][Full Text] [Related]
17. Reduced folate carrier-1 80G > A gene polymorphism is not associated with methotrexate treatment response in South Indian Tamils with rheumatoid arthritis. Muralidharan N; Mariaselvam CM; Mithun CB; Negi VS Clin Rheumatol; 2016 Apr; 35(4):879-85. PubMed ID: 25771854 [TBL] [Abstract][Full Text] [Related]
18. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Dervieux T; Furst D; Lein DO; Capps R; Smith K; Walsh M; Kremer J Arthritis Rheum; 2004 Sep; 50(9):2766-74. PubMed ID: 15457444 [TBL] [Abstract][Full Text] [Related]
19. Lack of association between CXCL9 and CXCL10 gene polymorphisms and the outcome of rheumatoid arthritis treatment with methotrexate. Kotrych D; Dziedziejko V; Safranow K; Pawlik A Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3037-40. PubMed ID: 26367725 [TBL] [Abstract][Full Text] [Related]
20. Polymorphisms and Pharmacogenomics for the Clinical Efficacy of Methotrexate in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis. Qiu Q; Huang J; Shu X; Fan H; Zhou Y; Xiao C Sci Rep; 2017 Mar; 7():44015. PubMed ID: 28266606 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]